Short Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Decreases By 17.1%

Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) saw a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 2,900 shares, a decrease of 17.1% from the April 30th total of 3,500 shares. Based on an average daily volume of 18,500 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the shares of the company are short sold.

Genenta Science Trading Up 16.5%

Shares of GNTA stock traded up $0.71 during mid-day trading on Friday, hitting $5.01. 2,713 shares of the stock were exchanged, compared to its average volume of 14,902. The firm has a fifty day moving average of $4.08 and a 200 day moving average of $4.27. Genenta Science has a 52-week low of $2.79 and a 52-week high of $7.28.

Institutional Trading of Genenta Science

A number of hedge funds have recently bought and sold shares of the business. Allianz SE raised its holdings in Genenta Science by 126.2% in the 1st quarter. Allianz SE now owns 233,550 shares of the company's stock valued at $927,000 after acquiring an additional 130,300 shares during the last quarter. Algebris UK Ltd raised its holdings in Genenta Science by 122.2% in the 1st quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock valued at $368,000 after acquiring an additional 55,000 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Genenta Science in the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 15.13% of the company's stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.